Evidence map›Paper›PMID 34723675›Full record

ArticleInternational journal of health services : planning, administration, evaluation2022

Measuring the Commercial Determinants of Health and Disease: A Proposed Framework.

Kelley Lee, Nicholas Freudenberg, Marco Zenone, Julia Smith, Melissa Mialon, Robert Marten, Joana Madureira Lima, Sharon Friel, Daniel Eisenkraft Klein, Eric Crosbie and 1 more

Abstract read
In one paragraph

Article in International journal of health services : planning, administration, evaluation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Preventing type 2 diabetes: a qualitative study exploring the complexity of health-related practices in people with prediabetes.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kelley Lee1763Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0002-3625-1915
Nicholas FreudenbergSchool of Public Health, 2009City University New York, New York, USA.
Marco Zenone156606London School of Hygiene & Tropical Medicine, London, UK.
Julia Smith1763Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Melissa MialonTrinity Business School, 8809Trinity College Dublin, Dublin, Ireland.ORCID 0000-0002-9883-6441
Robert MartenAlliance for Health Policy and Systems Research, 6851World Health Organization, Geneva, Switzerland.
Joana Madureira Lima3489WHO Regional Office for Europe, WHO Country Office in Kyrgyzstan.
Sharon FrielSchool of Regulation and Global Governance, 2219Australian National University, Canberra, Australia.
Daniel Eisenkraft KleinDalla Lana School of Public Health, 7938University of Toronto, Toronto, Canada.
Eric CrosbieSchool of Public Health, 6851University of Nevada Reno, Reno, USA.
Kent Buse571352George Institute for Global Health UK, Imperial College London, London, UK.ORCID 0000-0002-5485-0110

Funding

CIHR 429653World Health Organization 001
6 · The paper itself

Abstract

The commercial determinants of health (CDoH) describe the adverse health effects associated with for-profit actors and their actions. Despite efforts to advance the definition, conceptualization, and empirical analyses of CDoH, the term's practical application to mitigate these effects requires the capacity to measure the influences of specific components of CDoH and the cumulative impacts of CDoH on the health and well-being of specific populations. Building on the Global Burden of Disease Study, we begin by conceptualizing CDoH as risk factor exposures that span agency and structural influences. We identify 6 components of these influences and propose an initial set of indicators and datasets to rank exposures as high, medium, or low. These are combined into a commercial determinants of health index (CDoHi) and illustrated by 3 countries. Although now a proof of concept, comparative analysis of CDoH exposures by population, over time and space, and their associated health outcomes will become possible with further development of indicators and datasets. Expansion of the CDoHi and application to varied populations groups will enable finer targeting of interventions to reduce health harms. The measurement of improvements to health and wellness from such interventions will, in turn, inform overall efforts to address the CDoH.

Identifiers

PMID34723675
PMCPMC8592108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.